Nigella sativa supplementation to treat symptomatic mild COVID-19: A structured summary of a protocol for a randomised, controlled, clinical trial
AbstractObjectivesTo investigate the potential efficacy ofNigella sativa (NS) oil supplementation on the outcomes of patients with mild Coronavirus Disease 2019 (COVID-19).Trial designProspective, two-arm, parallel-group, randomised (1:1 allocation ratio), open-label, controlled, exploratory phase II clinical trial of oral NS oil in patients with mild COVID-19.ParticipantsInclusion Criteria:- Patients with mild COVID19 (defined as upper respiratory tract infection symptoms in the absence of clinical or radiological signs of pneumonia).- Adult (18 - 65 years old).- Written informed consent by the patient (or legally authorized representative) prior to initiation of any study procedures.- All patients should understand and agree to comply with planned study procedures.- Polymerase chain reaction (PCR)-confirmed infection with Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) from throat swab.Exclusion Criteria:- Patients with pneumonia or severe illness requiring admission to intensive care unit.- Severe chronic kidney disease (i.e. estimated glomerular filtration rate [eGFR] 5 times the upper limit of normal).- Pregnancy or breast feeding.- Anticipated transfer within 72 hours to another hospital that is not a study site.- Allergy to the study medicationThe trial is currently conducted on patients recruited from King Abdulaziz University Hospital, Jeddah, Saudi Arabia.Intervention and comparatorIntervention group:Nigella sativa oil (MARNYS ® Cuminmar) 500 mg sof...
CONCLUSIONS: After a combined burn injury and hemorrhage, DPR leads to increased survival in mice. Survival was similar with the use of normal saline or Delflex. DPR with normal saline reduced the inflammatory response seen with Delflex and delayed the progression of acute lung injury. DPR may be a valuable strategy in the treatment of patients with combined burn injury and hemorrhage. PMID: 32962326 [PubMed - in process]
Conclusions: Echocardiography may be useful for the management of selected COVID-19 patients, especially those with elevated D-Dimer and Troponin levels, in up to 16% of patients. PMID: 32963823 [PubMed]
Authors: Bertoli F, Veritti D, Danese C, Samassa F, Sarao V, Rassu N, Gambato T, Lanzetta P Abstract The novel pandemic coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has challenged the medical community. While diagnostic and therapeutic efforts have been focused on respiratory complications of the disease, several ocular implications have also emerged. SARS-CoV-2 RNA has been found in tears of the infected patients, and reports suggest that the ocular surface could serve as a portal of entry and a reservoir for viral transmission. Clinically, COVID-...
ConclusionThe association of eosinophilic pneumonia with Ustekinumab, a drug used in the treatment of psoriasis and other autoimmune diseases, is rare and there is a paucity of literature regarding this association. PMID: 32962463 [PubMed - as supplied by publisher]
Authors: Rodríguez-Martínez CE, Sinha IP, Whittaker E, Nagakumar P, Fernandes RM PMID: 32962456 [PubMed - as supplied by publisher]
Publication date: December 2020Source: Radiation Physics and Chemistry, Volume 177Author(s): Xiaqi Zhang, Fang Wang, Ming Weng, Meng Cao
Publication date: Available online 23 September 2020Source: Life SciencesAuthor(s): Somaye Sadeghi, Sara Soudi, Abbas Shafiee, Seyed Mahmoud Hashemi
Authors: Madubueze CE, Dachollom S, Onwubuya IO Abstract Coronavirus disease 2019 (COVID-19) is a disease caused by severe acute respiratory syndrome coronavirus 2 (SARS CoV-2). It was declared on March 11, 2020, by the World Health Organization as pandemic disease. The disease has neither approved medicine nor vaccine and has made governments and scholars search for drastic measures in combating the pandemic. Regrettably, the spread of the virus and mortality due to COVID-19 has continued to increase daily. Hence, it is imperative to control the spread of the disease particularly using nonpharmacological strategie...
Authors: Chukwudozie OS, Chukwuanukwu RC, Iroanya OO, Eze DM, Duru VC, Dele-Alimi TO, Kehinde BD, Bankole TT, Obi PC, Okinedo EU Abstract The novel coronavirus disease (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has previously never been identified with humans, thereby creating devastation in public health. The need for an effective vaccine to curb this pandemic cannot be overemphasized. In view of this, we designed a subcomponent antigenic peptide vaccine targeting the N-terminal (NT) and C-terminal (CT) RNA binding domains of the nucleocapsid protein that aid in viral replica...
[Premium Times] The Nigerian Centre for Disease Control (NCDC) has warned that there is likely to be an even more devastating second wave of coronavirus in Adamawa and other states in the country due to the non-compliance to COVID-19 health guidelines.
More News: Allergy | Allergy & Immunology | Breastfed | Chronic Kidney Disease | Clinical Trials | Computers | Coronavirus | COVID-19 | Dialysis | Hospitals | Intensive Care | Legislation | Liver | Liver Disease | Middle East Health | Pneumonia | Pregnancy | Research | Respiratory Medicine | SARS | Saudi Arabia Health | Study | Urology & Nephrology | Websites